Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.9K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.9K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

90
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
90
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

39
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
39
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

63
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
63
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

106
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
106
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

1.6K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiac angiosarcoma.

Acta cardiologica·2025
Same author

Comments on association of HbA1c with carotid artery plaques in patients with coronary heart disease.

Acta cardiologica·2023
Same author

[A new approach in coronary interventional cardiology: the distal radial approach].

Revue medicale de Liege·2022
Same author

[Inclisiran (Leqvio®), a potent cholesterol-lowering agent by inhibiting PCSK9 using small interfering RNA-based innovative therapy].

Revue medicale de Liege·2022
Same author

[Tricuspid regurgitation: transcatheter treatment by TriClip®].

Revue medicale de Liege·2022
Same author

[Heart failure with preserved ejection fraction (HFpEF). What's up?]

Revue medicale de Liege·2022
Same journal

[Nature prescriptions and health promotion : sharing experience from primary care].

Revue medicale de Liege·2026
Same journal

[Eco-health: shared perspectives on primary care practice].

Revue medicale de Liege·2026
Same journal

[The strategic role of primary care in emerging diseases : surveillance, research, and preparedness].

Revue medicale de Liege·2026
Same journal

[Environmental impact of medicines and approaches for more eco responsible use].

Revue medicale de Liege·2026
Same journal

[Climate change and skin].

Revue medicale de Liege·2026
Same journal

[From Silent Spring to neuronal silence : pesticides and neurodegenerative diseases].

Revue medicale de Liege·2026
See all related articles

Related Experiment Video

Updated: Oct 4, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.7K

[Reduced ejection fraction heart failure].

A Ancion1, M L Nguyen Trung1, P Lancellotti1

  • 1Service de Cardiologie, CHU Liège, Belgique.

Revue Medicale De Liege
|February 10, 2022
PubMed
Summary
This summary is machine-generated.

New heart failure guidelines recommend initiating all effective pharmacological treatments simultaneously for reduced ejection fraction. Rapid initiation and titration to maximum tolerated doses are crucial for improving patient outcomes.

Keywords:
Pharmacological treatmentRecommendationsHeart failure

More Related Videos

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.7K

Related Experiment Videos

Last Updated: Oct 4, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.7K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.7K

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Medicine

Background:

  • Heart failure with reduced ejection fraction (HFrEF) remains a significant cause of morbidity and mortality.
  • Previous guidelines recommended sequential initiation of HFrEF therapies.
  • Evidence supports a more rapid, combination-based approach to pharmacotherapy.

Framework:

  • The current guideline emphasizes a 'quadruple therapy' approach for HFrEF.
  • This involves the simultaneous initiation of four key drug classes: ACE inhibitors/ARBs/ARNIs, beta-blockers, MRA, and SGLT2 inhibitors.
  • The framework prioritizes rapid uptitration to maximally tolerated doses.

Implementation:

  • Clinicians should assess patient eligibility for all guideline-directed medical therapies (GDMTs) at diagnosis.
  • Concurrent initiation of GDMTs, where feasible, is recommended.
  • Regular follow-up is essential for monitoring tolerance and titrating doses effectively.

Implications:

  • This strategy aims to accelerate the benefits of GDMTs, reducing hospitalizations and mortality.
  • Early and comprehensive treatment can significantly improve quality of life for HFrEF patients.
  • Adherence to rapid initiation and titration protocols is key to achieving optimal clinical results.